Phase 1 Evaluation of SGN-ALPV in Patients with Advanced Solid Tumors Including GEJ Carcinoma, NSCLC, Gastric, Cervical, Ovarian, and Endometrial Cancers

The primary objective of this Phase 1 study is to evaluate the safety and tolerability of **SGN-ALPV** in patients with advanced solid tumors, including **gastroesophageal junction carcinoma**, **non-small cell lung cancer (NSCLC)**, **gastric cancer**, **cervical cancer**, **ovarian cancer**, **endometrial cancer**, **malignant ovarian germ cell tumor (GCT)**, **malignant testicular GCT**, and **malignant extragonadal GCT**. Understanding the safety profile of SGN-ALPV is clinically relevant as it will inform future studies and potential therapeutic applications for these malignancies. No secondary objectives are provided in the available data.

The clinical trial involves a total of **172 participants** diagnosed with various types of cancer, including **gastroesophageal junction carcinoma**, non-small cell lung cancer, gastric cancer, cervical cancer, ovarian cancer, endometrial cancer, and malignant germ cell tumors, excluding pure teratomas. The study population comprises both male and female subjects, with an age range that includes adults and older adults. Participants were selected based on specific criteria, although the principal inclusion criteria are not provided. The trial does not focus on a vulnerable population. Lifestyle factors such as diet, physical activity, or habits are not specified in the available data. The selection process ensures a diverse representation of individuals affected by the specified medical conditions.

The clinical trial is a **Phase 1** study designed to evaluate the investigational product SGN-ALPV in patients with advanced **solid tumors**. The trial is structured as a randomized, double-blind, and controlled study, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thereby minimizing bias. The trial commenced on May 30, 2022, and is projected to conclude by December 31, 2024. Participants will be involved in the study for its entire duration unless specific conditions necessitate early termination, such as adverse events or withdrawal of consent.

Study visits are systematically organized to ensure comprehensive data collection and participant safety. The initial visit, known as the inclusion or screening visit, involves assessing eligibility criteria to confirm participant suitability for the trial. Following successful screening, participants will undergo a series of follow-up visits at predetermined intervals. These visits are crucial for monitoring the participants' health status, evaluating the investigational product's efficacy, and identifying any potential side effects. The end-of-study visit marks the final assessment, where comprehensive evaluations are conducted to gather conclusive data on the investigational product's impact.

Participants are expected to remain in the study for its full duration unless they meet criteria for early termination, such as experiencing significant adverse effects or choosing to withdraw from the trial. The study encompasses a range of medical conditions, including **gastroesophageal junction carcinoma**, **non-small cell lung cancer (NSCLC)**, **gastric cancer**, **cervical cancer**, **ovarian cancer**, **endometrial cancer**, and various forms of **malignant germ cell tumors (GCT)**, excluding pure teratomas. The trial's design and procedures are meticulously crafted to ensure the collection of reliable data while prioritizing participant safety and well-being.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of May 30, 2022, and an estimated end date of December 31, 2024. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely involve standard methodologies appropriate for a Phase 1 study. These may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure efficacy. The schedule for measuring and collecting data will be aligned with the trial's timeline, ensuring systematic data collection and analysis. The trial's efficacy assessments will be conducted in accordance with established clinical trial protocols, ensuring the reliability and validity of the results.